Current management of lobular in situ neoplasia

Journal Belge de Radiologie

Volumn 91, Issue 4, 2008, Pages 166-170

  Liebens, Fabienne ^a   Cardinael, A S ^b,c   Schillings, A P ^d   Mendez, V ^e   Demoulin, C ^f   Cusumano, P ^a,g   Carly, B ^a   Faverly, D ^h   Rozenberg, S ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b Clinique Notre Dame   (Belgium)

^c JULES BORDET INSTITUTE   (Belgium)

^d Clinique Saint Pierre of Ottignies   (Belgium)

^e Institut Medical Edith Cavell   (Belgium)

^f Clinique Saint Joseph   (Belgium)

^g Breast Unit   (Belgium)

^h ForPath CMP Laboratory Pathology   (Belgium)

Author keywords

Breast neoplasms; Therapy

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; DIPEPTIDASE; DIPEPTIDASE 1; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; PLACEBO; PROTEIN P53; RALOXIFENE; TAMOXIFEN; UNCLASSIFIED DRUG; UVOMORULIN;

ADJUVANT THERAPY; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CATARACT; CHROMOSOME LOSS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE ASSOCIATION; DOCTOR PATIENT RELATION; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECHOGRAPHY; GENETIC PREDISPOSITION; HEALTH CARE QUALITY; HUMAN; IMMUNOPHENOTYPING; INCIDENCE; LOBULAR CARCINOMA IN SITU; MAMMOGRAPHY; MASTECTOMY; MENOPAUSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CYST; PATIENT CARE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT DURATION; UTERUS CANCER;

BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, LOBULAR; FEMALE; HUMANS;

EID: 51349155057     PISSN: 00217646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Haagensen C.D., Lane N., Lattes R., et al.: Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer, 1978, 42: 737-69.
2. Tavassoli F.A., Devilee P., editors. Tumours of the breast and female genital organs. 3rd ed. Lyon: IARC Press, 2003.
3. Arpino G., Allred D.C., Mohsin S.K., et al.: Lobular neoplasia. on core-needle biopsy: Clinical significance. Cancer, 2004, 101: 242-250.
4. Li C.I., Anderson B.O., Daling J.R., et al.: Changing incidence of lobular carcinoma in situ of the breast. Breast Cancer Res Treat, 2002, 75: 259-68.
5. Lakhani S. R., Audretsch W., et al. on behalf of EUSOMA: The management of lobular carcinoma in situ (LCIS). Is LCIS the same as ductal carcinoma in situ (DCIS)? European Journal of Cancer, 2006, 42 (14): 2205-2211.
6. Chuba P.J., Hamre M.R., Yap J., et al.: Bilateral Risk for Subsequent Breast Cancer After Lobular Carcinoma-In-Situ: Analysis of Surveillance, Epidemiology, and End Results Data. J Clin Oncol, 2005, 23: 5534-5541.
7. Reis-Filho J. S., Simpson P. T., Jones C., et al.: Pleomorphic lobular carcinoma of the breast: role of comprehensive molecular pathology in characterization of an entity. J Pathol, 2005, 207: 1-13.
8. Green A.R., Krivinskas S.,Young R, et al.: Loss of expression of chromosome 16q genes DPEP1 and CTCF in lobular carcinoma in situ of the breast. Breast Cancer Res Treat, 2008 Jan 23 [Epub ahead of print].
9. Liberman L., Sama M., Susnik B., et al.: Lobular carcinoma in situ at percutaneous breast biopsy: surgical biopsy findings. AJR, 1999, 173: 291-299.
10. Georgian-Smith D., Lawton T.J.: Calcifications of lobular carcinoma in situ of the breast: radiologic-pathologic correlation. AJR, 2001, 176: 1255-1259.
11. Shin S.J., Rosen P.P.: Excisional biopsy should be performed if lobular carcinoma in situ is seen on needle core biopsy. Arch Pathol Lab Med, 2002, 126: 697-701.
12. Port E.R., Park A., Borgen P.I., et al.: Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia. Ann Surg Oncol, 2007, 14: 1051-7 Epub 2007 Jan 7.
13. Lord S.J., Lei W., Craft P., et al.: A systematic review of the effectiveness of magnetic resonance imaging (MRI) as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur Journal of Cancer, 2007, 43: 1905-1917.
14. Bowman K., Munoz A., Mahvi D.M., et al.: Lobular neoplasia diagnosed at core biopsy does not mandate surgical excision. J Surg Res, 2007, 142: 275-80.
15. Esserman L.E., Lamea L.,Tanev S., et al.: Should the Extent of Lobular Neoplasia on Core Biopsy Influence the Decision for Excision? The Breast Journal, 2007, 13: 55-61.
16. Liebens F.P., Carly B., Pastijn A., et al.: Management of BRCA1/2 associated breast cancer: a systematic qualitative review of the state of knowledge in 2006. Eur J Cancer, 2007, 43: 238-57 Epub 2006 Nov 13.
17. Cutuli B., de Lafontan B., Quetin P., et al.: Breast-conserving surgery and radiotherapy: a possible treatment for lobular carcinoma in situ? Eur J Cancer, 2005, 41: 380-5.
18. Page D.L., Schuyler RA., Dupont W.D., et al.: Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet, 2003, 361: 125-129.
19. Fisher B., Costantino J. P., Wickerham D.L., et al.: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst, 1998, 90: 1371-88.
20. Cuzick J., Forbes J., Edwards R., et al.: First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet, 2002, 360: 817-824.
21. Bao T., Prowell T, Stearns V.: Chemoprevention of Breast cancer: tamoxifen, raloxifene, and beyond. Am J Ther, 2006, 13: 337-348.
22. Cuzick J., Powles T., Veronesi U., et al.: Overview of the main outcomes in breast-cancer prevention trials. Lancet, 2003, 361: 296-300.
23. Vogel V.G., Costantino J.P., Wickerham D.L., et al.: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA, 2006, 295: 2727-2741. Epub 2006 Jun 5. Erratum in: JAMA, 2006, 296: 2926.
24. Kendall A., Dowsett M.: Novel concepts for the chemoprevention of breast cancer through aromatase inhibition. Endocr Rel Cancer, 2006, 13: 827-837.
25. Kiluk J.V., Acs G., Hoover S.J.: High-Risk Benign Breast Lesions: Current Strategies in Management. Cancer Control, 2007, 14: 321-329.
26. Phillips K.A., Glendon G., Knight J.A.: Putting the risk of breast cancer in perspective. N Engl J Med, 1999, 340: 141-4.
27. Klein W.M., Stefanek M.E.: Cancer Risk Elicitation and Communication: Lessons from the Psychology of Risk Perception. CA Cancer J Clin, 2007, 57: 147-167.
28. Ravdin P.M., Siminoff I.A., Harvey J.A.: Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol, 1998, 16: 515-521.
29. Hopwood P., Howell A., Lalloo F., et al.: Do women understand the odds? Risk perceptions and recall of risk information in women with a family history of breast cancer. Community Genet, 2003, 6: 214-23.
30. Stewart M.: Effective Physician-patient communication and health outcomes: a review. Can Med Assoc J, 1995, 152: 1423-1433.
31. Phillips B., Ball C., Sackett D., et al.: Levels of Evidence and Grades of Recommendation. Oxford Centre for Evidence-based Medicine. 2001. www.cebm.net